BOSTON -- A leadless pacemaker reliably communicated with a subcutaneous implantable cardioverter-defibrillator (S-ICD) to deliver anti-tachycardia (ATP) and bradycardia pacing, the MODULAR ATP study ...

In a typical population of patients requiring implantable cardioverter-defibrillator (ICD) therapy without pacing, mostly for the primary prevention of sudden cardiac death, a subcutaneous ICD (S-ICD; ...

Please provide your email address to receive an email when new articles are posted on . “Prior research has established the subcutaneous ICD as a reasonable alternative to the transvenous ICD in ...

MANCHESTER, UK — There have been many recent advances in cardiac rhythm management, notably the use of leadless pacemakers and subcutaneous implantable cardioverter defibrillators (S-ICDs), experts ...

For older patients without an indication for pacing, the subcutaneous implantable cardioverter-defibrillator (S-ICD; Boston Scientific) provides results comparable to those seen with traditional ...

Please provide your email address to receive an email when new articles are posted on . A subcutaneous implantable cardioverter defibrillator was noninferior to a transvenous ICD regarding major ...

A leadless, partially subcutaneous left ventricular (LV) pacing system that can deliver cardiac resynchronization therapy (CRT) when added to dual-chamber pacing, already available in Europe, ...

Cleveland Clinic doctors were the first in the world to successfully implant leadless pacemaker defibrillator systems in two patients as part of a global clinical trial sponsored by Boston Scientific, ...

Electric shocks delivered by subcutaneous defibrillators are equally effective compared to shocks delivered by conventional transvenous defibrillators, according to a study published in the journal ...

Though the PRAETORIAN group was technically unable to prove that 8 years was enough to give a subcutaneous implantable cardioverter-defibrillator (ICD) an edge in safety, complication rates helped ...

EBR Systems, Inc., developer of the world’s only left ventricular wireless cardiac pacing device for heart failure, today announced that management will be presenting at the J.P. Morgan 2026 ...